Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program

Autor: Alexandre de Moura, Perrine Vuagnat, Benjamin Renouf, Jean-Yves Pierga, Delphine Loirat, Pauline Vaflard, Charline Lafayolle de la Bruyère, Natacha Chaumard-Billotey, Nawale Hajjaji, Sylvain Ladoire, Sandrine Dabakuyo, Anne Patsouris, Jean Sébastien Frenel, Vincent Nicolai, Marie Alexandre, Nadine Dohollou, Julien Grenier, Heloïse Bourien, François-Clément Bidard

Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)

Abstract Following the results of the IMpassion130 trial, an early access program (EAP) was opened in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (aTNBC) to receive a combination of paclitaxel and atezolizumab

Externí odkaz: https://doaj.org/article/32a11dfa386a4c37a6ba7f6ce998b444

Trends in clinical characteristics and outcomes of all critically ill COVID-19 adult patients hospitalized in France between March 2020 and June 2021: a national database study

Autor: Diane Naouri, Albert Vuagnat, Gaëtan Beduneau, Martin Dres, Tai Pham, Alain Mercat, Alain Combes, Alexandre Demoule, Antoine Kimmoun, Matthieu Schmidt, Matthieu Jamme

Publikováno v: Annals of Intensive Care, Vol 13, Iss 1, Pp 1-9 (2023)

Abstract Introduction Studies regarding coronavirus disease 2019 (COVID-19) were mainly performed in the initial wave, but some small-scale data points to prognostic differences for patients in successive waves. We therefore aimed to study the impact

Externí odkaz: https://doaj.org/article/0d5646848e3845878345f406f6bf28bc

Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study

Autor: Francoise Difoum, Antoine Schernberg, Hélène Vanquaethem, Hugo Picchi, Audrey Le Roy, Perrine Vuagnat, Carole Helissey

Publikováno v: Cancer Reports, Vol 6, Iss 7, Pp n/a-n/a (2023)

Abstract Background Immunotherapy alone or in combination has clearly improved the survival of patients with lung cancer. However, it may also be responsible for adverse events impacting these patients' quality of life. The ToxImmune study aims to id

Externí odkaz: https://doaj.org/article/22f697b8a3cf49a78c02ebcd202ae0be

Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.

Autor: de Moura, Alexandre^1,2 (AUTHOR) alexandre.demoura@curie.fr, Vuagnat, Perrine^1,2 (AUTHOR), Renouf, Benjamin¹ (AUTHOR), Pierga, Jean-Yves^1,3 (AUTHOR), Loirat, Delphine¹ (AUTHOR), Vaflard, Pauline¹ (AUTHOR), Lafayolle de la Bruyère, Charline⁴ (AUTHOR), Chaumard-Billotey, Natacha⁵ (AUTHOR), Hajjaji, Nawale^6,7 (AUTHOR), Ladoire, Sylvain⁸ (AUTHOR), Dabakuyo, Sandrine⁸ (AUTHOR), Patsouris, Anne⁹ (AUTHOR), Frenel, Jean Sébastien⁹ (AUTHOR), Nicolai, Vincent¹⁰ (AUTHOR), Alexandre, Marie¹¹ (AUTHOR), Dohollou, Nadine¹² (AUTHOR), Grenier, Julien¹³ (AUTHOR), Bourien, Heloïse¹⁴ (AUTHOR), Bidard, François-Clément^1,2 (AUTHOR)

Publikováno v: Scientific Reports. 11/20/2023, Vol. 13 Issue 1, p1-7. 7p.

Impact of ICU transfers on the mortality rate of patients with COVID-19: insights from comprehensive national database in France

Autor: Marc-Antoine Sanchez, Albert Vuagnat, Olivier Grimaud, Emmanuelle Leray, Jean-Marc Philippe, François-Xavier Lescure, Mathieu Boutonnet, Hélène Coignard, Agnès Ricard Hibon, Stephane Sanchez, Julien Pottecher

Publikováno v: Annals of Intensive Care, Vol 11, Iss 1, Pp 1-11 (2021)

Abstract Background The first wave of the COVID-19 pandemic confronted healthcare systems around the world with unprecedented organizational challenges, particularly regarding the availability of intensive care unit (ICU) beds. One strategy implement

Externí odkaz: https://doaj.org/article/636771b4dde84c0aab47bdedf5a32de9